JP2025020303A5 - - Google Patents

Download PDF

Info

Publication number
JP2025020303A5
JP2025020303A5 JP2024193448A JP2024193448A JP2025020303A5 JP 2025020303 A5 JP2025020303 A5 JP 2025020303A5 JP 2024193448 A JP2024193448 A JP 2024193448A JP 2024193448 A JP2024193448 A JP 2024193448A JP 2025020303 A5 JP2025020303 A5 JP 2025020303A5
Authority
JP
Japan
Prior art keywords
drug delivery
delivery system
injected
fas
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024193448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025020303A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/065423 external-priority patent/WO2021127052A1/en
Application filed filed Critical
Publication of JP2025020303A publication Critical patent/JP2025020303A/ja
Publication of JP2025020303A5 publication Critical patent/JP2025020303A5/ja
Pending legal-status Critical Current

Links

JP2024193448A 2019-12-18 2024-11-05 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系 Pending JP2025020303A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962949773P 2019-12-18 2019-12-18
US62/949,773 2019-12-18
PCT/US2020/065423 WO2021127052A1 (en) 2019-12-18 2020-12-16 DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR
JP2022537646A JP2023507603A (ja) 2019-12-18 2020-12-16 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022537646A Division JP2023507603A (ja) 2019-12-18 2020-12-16 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系

Publications (2)

Publication Number Publication Date
JP2025020303A JP2025020303A (ja) 2025-02-12
JP2025020303A5 true JP2025020303A5 (https=) 2025-08-20

Family

ID=76478085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537646A Pending JP2023507603A (ja) 2019-12-18 2020-12-16 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系
JP2024193448A Pending JP2025020303A (ja) 2019-12-18 2024-11-05 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022537646A Pending JP2023507603A (ja) 2019-12-18 2020-12-16 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系

Country Status (8)

Country Link
US (1) US20230094423A1 (https=)
EP (1) EP4076495A4 (https=)
JP (2) JP2023507603A (https=)
KR (1) KR20220118499A (https=)
CN (1) CN115119501A (https=)
AU (2) AU2020407072B2 (https=)
CA (1) CA3162324A1 (https=)
WO (1) WO2021127052A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4565596A1 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4565595A2 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
JP2003522160A (ja) * 2000-02-11 2003-07-22 ジェンベク、インコーポレイティッド 眼関連疾患の治療のための遺伝子治療
EP1737483A2 (en) * 2004-04-23 2007-01-03 University of Pittsburgh of the Commonwealth System of Higher Education Cell death modulation via antagonists of fasl and fas activation
US8592374B2 (en) * 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
CA2722971C (en) * 2008-05-09 2019-05-07 Qlt Plug Delivery, Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
WO2010102052A2 (en) * 2009-03-03 2010-09-10 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
CN104640568B (zh) * 2012-07-18 2016-10-19 阿珀吉尼科斯股份公司 用于治疗mds的cd95信号传导途径的抑制剂
US10508134B2 (en) * 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
CA2986769A1 (en) * 2015-05-27 2016-12-01 Neurotech Usa, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders
WO2019246141A1 (en) * 2018-06-19 2019-12-26 Cella Therapeutics, Llc DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统

Similar Documents

Publication Publication Date Title
JP2025020303A5 (https=)
Eid et al. Recombinant human erythropoietin for neuroprotection: what is the evidence?
US20180235934A1 (en) Noradrenergic drug treatment of obstructive sleep apnea
ES2886542T3 (es) Uso de sirolimus para tratar la degeneración macular asociada con la edad exudativa con edema persistente
JPH11507951A (ja) セレジリン投与による末梢ニューロパシーの予防および治療方法
US20060293270A1 (en) Methods and compositions for treating ocular disorders
JP2025159233A5 (https=)
US20240269343A1 (en) Use of immune modulators to improve nerve regeneration
CN110678193A (zh) 治疗和神经保护肽
US20210000919A1 (en) Activators of cxcr3 for the treatment of angiopathies of the eye
US20150141340A1 (en) Method of treating and preventing ocular angiogenesis
US20120058099A1 (en) Use of hypoxanthine for promotion of neuronal outgrowth
US6268340B1 (en) In vivo regeneration of oligodendrocytes by bolus injection of NGFβ
JP7459298B2 (ja) 細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物
WO1996028180A9 (en) Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
US20240285831A1 (en) Methods of use of modulators to improve nerve regeneration
US5830857A (en) Method of treating epilepsy
JP2024536479A5 (https=)
US20080138350A1 (en) Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery
RU2124875C1 (ru) Способ лечения больных с частичной атрофией зрительных нервов
Mikheytseva et al. Тherapy with the angiotensin-converting enzyme inhibitor zofenopril as a new direction in the treatment of primary glaucoma
CN1049602C (zh) 治疗缺血性眼病的复方注射液
US20040259844A1 (en) Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
JP2002154985A (ja) 眼疾患治療剤
JP3143916B2 (ja) ヒトｂｃｄｆを含有するパーキンソン病治療支持剤